Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
June 02, 2022 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
May 16, 2022 17:15 ET
|
Aerovate Therapeutics, Inc.
AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the pathophysiology of PAH PAH is an area of high...
Aerovate Therapeutics Announces First Quarter 2022 Financial Results
May 16, 2022 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Announces Full-Year 2021 Financial Results
March 30, 2022 16:45 ET
|
Aerovate Therapeutics, Inc.
Initiated IMPAHCT, a global Phase 2b/Phase 3 trial of AV-101 for pulmonary arterial hypertension (PAH) in December 2021Received FDA guidance in April 2021 that our Phase 2b/Phase 3 trial could support...
Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference
March 02, 2022 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension
December 15, 2021 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Announces Third Quarter 2021 Financial Results
November 15, 2021 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index
September 17, 2021 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Announces Second Quarter 2021 Financial Results
August 16, 2021 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors
July 19, 2021 08:00 ET
|
Aerovate Therapeutics, Inc.
BOSTON, July 19, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of...